Lilly loses arbitration over Canadian patents
By 
Sarah Houlton2017-03-29T11:19:00
Firm had sought recompense under the Nafta trade agreement
Eli Lilly has lost the North American Free Trade Agreement (Nafta) arbitration tribunal it had brought against the Canadian government. Canadian courts had invalidated its patents on atomexetine (Strattera) and olanzapine (Zyprexa), and the company was claiming C$500 million (£300 million) in damages from the country, representing its lost profits